Office of the Commissioner of Lobbying of Canada Office of the Commissioner of Lobbying of Canada

Language selection

Registry of Lobbyists

Registration - In-house Corporation

Novartis Pharmaceuticals Canada Inc. / Pedro Ferreira, Country President

Registration Information

In-house Corporation name: Novartis Pharmaceuticals Canada Inc.
Responsible Officer Name: Pedro Ferreira, Country President 
Responsible Officer Change History
Initial registration start date: 2007-07-13
Registration status: Active
Registration Number: 955937-15599

Associated Communications

Total Number of Communication Reports: 68

Monthly communication reports in the last 6 months: 4

Version 32 of 36 (2022-06-01 to 2022-10-05)

Version 32 of 36 (2022-06-01 to 2022-10-05)



Responsible Officer Name

This is the responsible officer name as provided in the most recent registration for the corporation or organization.

Name Change History:

Novartis Pharmaceuticals Canada Inc.

The following names have been used on or after July 2, 2008

The following names have been used on or after July 2, 2008
Name From To
Novartis Pharmaceuticals Canada Inc. 2010-01-04 current

The following names have been used before July 2, 2008

  • Novartis Pharmaceuticals Canada Inc.

Responsible Officer Change History

Novartis Pharmaceuticals Canada Inc.

Responsible Officer History
Responsible Officer Name From (YYYY-MM-DD) To (YYYY-MM-DD)
Pedro Ferreira 2023-10-01 Current
Andrea Marazzi 2022-06-01 2023-10-01
Christian Macher 2019-05-01 2022-06-01
Thea Discepola 2019-03-01 2019-05-01
Janice Murray 2017-05-01 2019-03-01
Timothy Maloney 2014-04-01 2017-05-01
Riad Sherif 2011-12-02 2014-04-01
Tom Rossi 2010-01-04 2011-02-02
David Meek 2007-07-13 2008-06-30

All Monthly Communication Reports for Novartis Pharmaceuticals Canada Inc.

Pedro Ferreira, Country President (Corporation)

Learn more...

Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.

Note: Monthly Communication Reports are due on the 15th day of each month for communications that took place in the previous month.

Results below are sorted by posted date, beginning with the most recent.

Results 1-68 of 68

  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Christopher Johnstone, Assistant Deputy minister | Health Canada (HC)
    • Simon Kennedy, Sous-ministre | Innovation, Science and Economic Development Canada (ISED)
    • Darryl Patterson, Director General | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Industry, Science and Technology, Health, Research and Development
    Communication date: 2023-09-20
    Posted date: 2023-10-16
    Communication number: 15599-577623 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Mark Holland, Minister of Health | Health Canada (HC)

    Subject Matter of the communication: Science and Technology, Health
    Communication date: 2023-08-17
    Posted date: 2023-09-15
    Communication number: 15599-575231 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jocelyne Voisin, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Science and Technology, Health, Research and Development
    Communication date: 2023-06-23
    Posted date: 2023-06-28
    Communication number: 15599-570777 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Sandenga Yeba, Senior Policy Advisor | Minister's Office | Health Canada (HC)
    • Jean-Sébastien Bock, Director of Policy | Minister's Office | Health Canada (HC)
    • Jean-Yves Duclos, Minister of Health | Health Canada (HC)

    Subject Matter of the communication: Industry, Science and Technology, Health, Research and Development
    Communication date: 2023-06-22
    Posted date: 2023-07-15
    Communication number: 15599-570776 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Andy Fillmore, Member of Parliament | House of Commons

    Subject Matter of the communication: Industry, Science and Technology, Health
    Communication date: 2023-06-06
    Posted date: 2023-07-15
    Communication number: 15599-567885 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Bianca Hossain, Policy advisor | Minister's Office | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Industry, Science and Technology, Health, Research and Development
    Communication date: 2023-04-25
    Posted date: 2023-05-15
    Communication number: 15599-565047 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jocelyne Voisin, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Industry, Science and Technology, Health
    Communication date: 2023-04-25
    Posted date: 2023-05-15
    Communication number: 15599-565044 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Dr. Stephen Ellis, Member of Parliament | House of Commons

    Subject Matter of the communication: Industry, Science and Technology, Health, Research and Development
    Communication date: 2023-04-24
    Posted date: 2023-05-15
    Communication number: 15599-565036 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Andy Fillmore, Member of Parliament | House of Commons

    Subject Matter of the communication: Industry, Science and Technology, Health, Research and Development
    Communication date: 2023-04-05
    Posted date: 2023-05-15
    Communication number: 15599-561247 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Bianca Hossain, Policy advisor | Minister's Office | Innovation, Science and Economic Development Canada (ISED)
    • Jaxson Khan, Policy Advisor | Minister's Office | Innovation, Science and Economic Development Canada (ISED)
    • Pierre-Yves Bourque, Director of Operations | Ministers Office | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Science and Technology, Health
    Communication date: 2023-03-10
    Posted date: 2023-04-15
    Communication number: 15599-561244 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Chris Zou, Policy Advisor | Office of Minister International Trade | Global Affairs Canada (GAC)

    Subject Matter of the communication: Science and Technology, Health
    Communication date: 2023-01-10
    Posted date: 2023-02-15
    Communication number: 15599-553546 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Dr. Stephen Ellis, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Research and Development
    Communication date: 2023-01-04
    Posted date: 2023-02-15
    Communication number: 15599-553544 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Alexandre Boulé, Director Regional Affairs | Minister's Office | Canadian Heritage (PCH)
    • Ashley Wright, Chief of Staff to the Minister | Minister's Office | Pacific Economic Development Canada (PacifiCan)
    • Camille Benoit-Blouin, Special Assistant, Policy | Minister's Office International Trade, Export Promotion, Small Business and Economic Development | Global Affairs Canada (GAC)
    • Chris Zou, Policy Advisor | Office of the Minister of International Trade, Export Promotion, Small Business and Economic Development | Global Affairs Canada (GAC)
    • Zachary Nixon, Chief of Staff to the Minister | Minister's Office International Trade | Global Affairs Canada (GAC)
    • Jessie Pierre, Director of Policy | Ministers office | Federal Economic Development Agency for Southern Ontario (FedDev)

    Subject Matter of the communication: Industry, Science and Technology, Health, Research and Development
    Communication date: 2022-11-23
    Posted date: 2022-12-15
    Communication number: 15599-548550 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jean-Yves Duclos, Minister of Health | Health Canada (HC)

    Subject Matter of the communication: Industry, Health
    Communication date: 2022-09-29
    Posted date: 2022-10-15
    Communication number: 15599-542675 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Seamus O'Regan, Minister of Labour | Employment and Social Development Canada (ESDC)

    Subject Matter of the communication: Industry, Health
    Communication date: 2022-07-21
    Posted date: 2022-08-15
    Communication number: 15599-539071 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Simon Kennedy, Sous-ministre | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Industry, Intellectual Property, Science and Technology, Health, International Trade
    Communication date: 2022-06-28
    Posted date: 2022-07-04
    Communication number: 15599-536618 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Stephen Lucas, Sous-ministre | Health Products and food branch | Health Canada (HC)
    • Nancy Hamzawi, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Industry, Intellectual Property, Science and Technology, Health, International Trade
    Communication date: 2022-06-17
    Posted date: 2022-07-04
    Communication number: 15599-536615 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Alexandre Boulerice, Member of Parliament | House of Commons

    Subject Matter of the communication: Industry, Health
    Communication date: 2022-05-31
    Posted date: 2022-06-05
    Communication number: 15599-533291 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Bernard Genereux, Member of Parliament | House of Commons
    • Jacques Gourde, Member of Parliament | House of Commons
    • Richard Martel, Member of Parliament | House of Commons
    • Luc Berthold, Député | House of Commons
    • Richard Lehoux, Member of Parliament | House of Commons

    Subject Matter of the communication: Industry, Health
    Communication date: 2022-05-31
    Posted date: 2022-06-05
    Communication number: 15599-533290 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Adam Van Koeverden, Member of Parliament | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2022-05-31
    Posted date: 2022-06-05
    Communication number: 15599-533289 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Dr. Stephen Ellis, Member of Parliament | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2022-05-31
    Posted date: 2022-06-05
    Communication number: 15599-533288 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Karl Sasseville, Deputy Chief of Staff | Minister's Office | Health Canada (HC)
    • Jamie Kippen, Chief of Staff | Minister's Office | Health Canada (HC)
    • Jean-Sébastien Bock, Director of Policy | Minister's Office | Health Canada (HC)
    • Jean-Yves Duclos, Minister of Health | Health Canada (HC)
    • Sandenga Yeba, Senior Policy Advisor | Minister's Office | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2022-05-31
    Posted date: 2022-06-05
    Communication number: 15599-533287 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Eric Costen, Senior Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • Simon Kennedy, Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Industry, Science and Technology, Health
    Communication date: 2022-05-30
    Posted date: 2022-06-08
    Communication number: 15599-533578 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Sandenga Yeba, Conseiller principal, Politiques - bureau de Quebec | Cabinet du ministre | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2022-03-25
    Posted date: 2022-03-25
    Communication number: 15599-527074 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Tom Kmiec, Member of Parliament, Calgary Shephard | House of Commons

    Subject Matter of the communication: Health, Research and Development
    Communication date: 2022-03-03
    Posted date: 2022-04-16
    Communication number: 15599-524431 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jean-Sébastien Bock, Directeur des politiques | Santé Canada | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2022-02-14
    Posted date: 2022-02-14
    Communication number: 15599-522420 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Luc Berthold, Député | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2022-01-27
    Posted date: 2022-02-14
    Communication number: 15599-522416 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jean-Yves Duclos, Ministre de la santé | Cabinet du ministre | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2021-12-09
    Posted date: 2021-12-16
    Communication number: 15599-518449 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Luc Berthold, Député | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2021-12-06
    Posted date: 2021-12-16
    Communication number: 15599-518450 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jean-Sebastien Bock, Director of Policy | Health Canada (HC)
    • Miro Froehlich, Policy Advisor | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2021-12-01
    Posted date: 2021-12-03
    Communication number: 15599-516527 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Marc Miller, Minister of Indigenous Services | Indigenous Services Canada (ISC)

    Subject Matter of the communication: Industry, Science and Technology, Health
    Communication date: 2021-11-22
    Posted date: 2021-12-15
    Communication number: 15599-516636 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • François-Philippe Champagne, Minister of Innovation Science and Industry | Minister's Office | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Industry, Science and Technology, Health
    Communication date: 2021-11-09
    Posted date: 2021-12-15
    Communication number: 15599-516635 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Erin O'Toole, Member of Parliament, Official Leader of the Opposition | House of Commons

    Subject Matter of the communication: Industry, Science and Technology, Health, Research and Development
    Communication date: 2021-07-07
    Posted date: 2021-08-16
    Communication number: 15599-511882 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Erin O'Toole, Member of Parliament | House of Commons
    • Richard Martel, Member of Parliament | House of Commons
    • Pierre Paul-Hus, Member of Parliament | House of Commons

    Subject Matter of the communication: Industry, Science and Technology, Health, Research and Development
    Communication date: 2021-06-21
    Posted date: 2021-07-15
    Communication number: 15599-509772 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Luc Thériault, Member of Parliament | House of Commons

    Subject Matter of the communication: Industry, Science and Technology, Health
    Communication date: 2021-06-04
    Posted date: 2021-07-15
    Communication number: 15599-509771 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Holly Duggan, Stakeholder Relations Advisor | Office of the Leader of the Opposition | House of Commons
    • Jordan Matte, Policy Advisor | Office of the Leader of the Opposition | House of Commons
    • Alexander MacDonald, Policy Advisor | Office of the Leader of the Opposition | House of Commons

    Subject Matter of the communication: Industry, Science and Technology, Health
    Communication date: 2021-06-01
    Posted date: 2021-07-15
    Communication number: 15599-506648 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Senior Policy Advisor | Office of the Minister | Health Canada (HC)
    • Sabina Saini, Chief of Staff | Office of the Minister | Health Canada (HC)

    Subject Matter of the communication: Science and Technology, Health, Research and Development
    Communication date: 2021-05-20
    Posted date: 2021-06-15
    Communication number: 15599-506656 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jean Yip, Member of Parliament | House of Commons
    • Joey Wong, Special Assistant to Jean Yip, MP | House of Commons

    Subject Matter of the communication: Science and Technology, Health, Research and Development
    Communication date: 2021-05-19
    Posted date: 2021-06-15
    Communication number: 15599-506654 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Mike Lake, Member of Parliament | House of Commons
    • Jaclyn Preece, Constituency Manager | House of Commons
    • Nina Childs, Constituency Manager | House of Commons

    Subject Matter of the communication: Science and Technology, Health, Research and Development
    Communication date: 2021-05-19
    Posted date: 2021-06-15
    Communication number: 15599-506651 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jean Yip, Member of Parliament | House of Commons

    Subject Matter of the communication: Industry, Health
    Communication date: 2021-04-30
    Posted date: 2021-05-15
    Communication number: 15599-503463 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Alexandre Deslongchamps, Director of Operations | Minister's Office | Natural Resources Canada (NRCan)

    Subject Matter of the communication: Industry, Health
    Communication date: 2021-04-29
    Posted date: 2021-05-15
    Communication number: 15599-503462 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • François-Philippe Champagne, Minister of Innovation Science and Economic Development (ISED) | Minister's Office | Innovation, Science and Economic Development Canada (ISED)
    • Amanda Woodley, Policy Advisor | Ministers Office | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Industry, Intellectual Property, Health, International Trade
    Communication date: 2021-04-29
    Posted date: 2021-05-15
    Communication number: 15599-503461 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Celine Caira, Senior Policy Advisor | Minister's Office | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Industry, Science and Technology, Health, Research and Development
    Communication date: 2021-04-26
    Posted date: 2021-05-15
    Communication number: 15599-503195 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Andy Fillmore, Member of Parliament, Halifax | House of Commons

    Subject Matter of the communication: Industry, Science and Technology, Health, Research and Development
    Communication date: 2021-04-22
    Posted date: 2021-05-15
    Communication number: 15599-503196 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Sean Fraser, Member of Parliament | House of Commons

    Subject Matter of the communication: Industry, Science and Technology, Health, Research and Development
    Communication date: 2021-04-16
    Posted date: 2021-05-15
    Communication number: 15599-503197 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • François-Philippe Champagne, Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Industry, Science and Technology, Health, Research and Development
    Communication date: 2021-02-01
    Posted date: 2021-03-15
    Communication number: 15599-494289 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Tom Kmiec, Member of Parliament, Calgary Shephard | House of Commons

    Subject Matter of the communication: Science and Technology, Health, Research and Development
    Communication date: 2021-02-01
    Posted date: 2021-03-15
    Communication number: 15599-494288 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • François-Philippe Champagne, Ministre | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Industry
    Communication date: 2021-02-01
    Posted date: 2021-02-01
    Communication number: 15599-494283 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Mike Dossou, Legislative Assistant | Member of Parliament's staff Dorval Lachine Lasalle | House of Commons

    Subject Matter of the communication: Research and Development
    Communication date: 2021-01-26
    Posted date: 2021-02-15
    Communication number: 15599-494287 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Chris d"Entremont, Member of Parliament | House of Commons

    Subject Matter of the communication: Industry, Science and Technology, Health
    Communication date: 2020-11-19
    Posted date: 2020-12-15
    Communication number: 15599-488652 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Shauna Roddey, Special Assistant | Innovation, Science and Economic Development Canada (ISED)
    • Mollie Anderson, Special Assistant | Innovation, Science and Economic Development Canada (ISED)
    • Liana Iannantuono, Special Assistant | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Industry, Science and Technology, Health
    Communication date: 2020-10-20
    Posted date: 2020-11-16
    Communication number: 15599-485652 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Adam Van Koeverden, Député | House of Commons

    Subject Matter of the communication: Justice and Law Enforcement
    Communication date: 2020-10-07
    Posted date: 2020-10-07
    Communication number: 15599-483485 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Bardish Chagger, Ministre | Diversité et Inclusion et de la jeunesse | Canadian Heritage (PCH)
    • Jamie Kippen, Chef de Cabinet | Diversité et Inclusion et de la jeunesse | Canadian Heritage (PCH)

    Subject Matter of the communication: Justice and Law Enforcement
    Communication date: 2020-09-02
    Posted date: 2020-09-14
    Communication number: 15599-481712 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Tom Kmiec, Member of Parliament, Calgary | House of Commons
    • Kelly McCauley, Member of Parliament, Edmonton | House of Commons

    Subject Matter of the communication: Science and Technology, Health, Research and Development
    Communication date: 2020-07-13
    Posted date: 2020-08-15
    Communication number: 15599-477280 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Pierre Sabourin, Assistant Deputy Minister | Health Products and Food Branch | Health Canada (HC)

    Subject Matter of the communication: Health, Research and Development
    Communication date: 2020-04-09
    Posted date: 2020-05-15
    Communication number: 15599-471460 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Anju Dhillon, Member of Parliament | House of Commons

    Subject Matter of the communication: Science and Technology, Health, Research and Development
    Communication date: 2020-02-11
    Posted date: 2020-03-16
    Communication number: 15599-464775 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Justin Trudeau, Prime Minister | Prime Minister's Office (PMO)

    Subject Matter of the communication: Science and Technology, Health, Research and Development
    Communication date: 2019-12-11
    Posted date: 2020-01-15
    Communication number: 15599-462333 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • William Monreau, Minister | Finance Canada (FIN)
    • Ben Chin, Chief of Staff | Finance Canada (FIN)

    Subject Matter of the communication: Industry, Intellectual Property, Science and Technology, Health, International Trade, Research and Development
    Communication date: 2019-01-25
    Posted date: 2019-02-15
    Communication number: 15599-445212 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Simon Kennedy, Deputy Minister | Health Canada (HC)
    • Abby Hoffman, Assistant Deputy Minister | Strategic Policy Branch | Health Canada (HC)
    • Kathyrn Nowers, Director of Policy | Office of the Minister | Health Canada (HC)
    • John Knubley, Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • Eric Dagenais, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • Paul Halucha, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • David McFarlane, Director of Policy | Office of the Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Industry, Intellectual Property, Science and Technology, Health, International Trade
    Communication date: 2018-10-05
    Posted date: 2018-11-15
    Communication number: 15599-435115 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Ginette Petitpas Taylor, Minister of Health | Health Canada (HC)
    • Simon Kennedy, Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Industry, Science and Technology, Health, Research and Development
    Communication date: 2018-06-28
    Posted date: 2018-07-16
    Communication number: 15599-430658 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Scott Brison, President, Treasury Board of Canada | Treasury Board Of Canada Secretariat (TBS)
    • Farees Nathoo, Special Assistant, Communications | Treasury Board Of Canada Secretariat (TBS)
    • Pat Dorsey, VP ACOA, PEI | Atlantic Canada Opportunities Agency (ACOA)

    Subject Matter of the communication: Industry, Science and Technology, Health, Research and Development
    Communication date: 2018-06-05
    Posted date: 2018-07-16
    Communication number: 15599-427971 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Susan Bincoletto, Ambassador | Global Affairs Canada (GAC)

    Subject Matter of the communication: Industry, Intellectual Property, Science and Technology, Health, Research and Development
    Communication date: 2018-05-22
    Posted date: 2018-06-11
    Communication number: 15599-427973 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Anju Dhillon, Member of Parliament, Dorval-Lachine-LaSalle | House of Commons

    Subject Matter of the communication: Industry, Science and Technology, Health, International Trade, Research and Development
    Communication date: 2018-05-08
    Posted date: 2018-06-15
    Communication number: 15599-425668 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Ginette Petitpas Taylor, Health Minister | Health Canada (HC)

    Subject Matter of the communication: Industry, Science and Technology, Health
    Communication date: 2018-05-05
    Posted date: 2018-06-15
    Communication number: 15599-426076 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Abby Hoffman, Assistant Deputy Minister | Strategic Policy | Health Canada (HC)
    • Eric Dagenais, Assistant Deputy Minister | Innovation Science and Economic Development | Innovation, Science and Economic Development Canada (ISED)
    • Simon Kennedy, Deputy Minister | Health Canada (HC)
    • John Knubley, Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • Gianluca Cairo, Chief of Staff | Innovation, Science and Economic Development Canada (ISED)
    • David MacFarlane, Director of Policy | Innovation, Science and Economic Development Canada (ISED)
    • Genevieve Hinse, Chief of Staff | Health Canada (HC)
    • Kathryn Nowers, Director of Policy | Health Canada (HC)
    • Hilary Travis, Special Assistant | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Industry, Science and Technology, Health
    Communication date: 2018-04-03
    Posted date: 2018-04-12
    Communication number: 15599-423586 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Anju Dhillon, Member of Parliament - Dorval-Lachine-Lasalee | Patented Medicine Prices Review Board (PMPRB)

    Subject Matter of the communication: Industry, Intellectual Property, Science and Technology, Health, Research and Development
    Communication date: 2017-10-12
    Posted date: 2017-11-15
    Communication number: 15599-410410 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Ron Parker, Senior Assistant Deputy Minister | Industry Canada
    • Ron Parker, Senior Assistant Deputy Minister | Industry Canada | Industry Canada

    Subject Matter of the communication: Industry, Intellectual Property, Science and Technology, Health
    Communication date: 2010-06-01
    Posted date: 2010-07-28
    Communication number: 15599-152804 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Louis Lévesque, Deputy Minister, International Trade | Foreign Affairs and International Trade Canada (DFAITC)

    Subject Matter of the communication: Industry, Intellectual Property, Science and Technology, Health
    Communication date: 2010-06-01
    Posted date: 2010-07-28
    Communication number: 15599-152803 View associated registration

Monthly Communication Reports in the last 6 Months for Novartis Pharmaceuticals Canada Inc.

Pedro Ferreira, Country President (Corporation)

Learn more...

Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.

Note: Monthly Communication Reports are due on the 15th day of each month for communications that took place in the previous month.

Results below are sorted by posted date, beginning with the most recent.

Results 1-68 of 68

  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Christopher Johnstone, Assistant Deputy minister | Health Canada (HC)
    • Simon Kennedy, Sous-ministre | Innovation, Science and Economic Development Canada (ISED)
    • Darryl Patterson, Director General | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Industry, Science and Technology, Health, Research and Development
    Communication date: 2023-09-20
    Posted date: 2023-10-16
    Communication number: 15599-577623 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Mark Holland, Minister of Health | Health Canada (HC)

    Subject Matter of the communication: Science and Technology, Health
    Communication date: 2023-08-17
    Posted date: 2023-09-15
    Communication number: 15599-575231 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jocelyne Voisin, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Science and Technology, Health, Research and Development
    Communication date: 2023-06-23
    Posted date: 2023-06-28
    Communication number: 15599-570777 View associated registration
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Sandenga Yeba, Senior Policy Advisor | Minister's Office | Health Canada (HC)
    • Jean-Sébastien Bock, Director of Policy | Minister's Office | Health Canada (HC)
    • Jean-Yves Duclos, Minister of Health | Health Canada (HC)

    Subject Matter of the communication: Industry, Science and Technology, Health, Research and Development
    Communication date: 2023-06-22
    Posted date: 2023-07-15
    Communication number: 15599-570776 View associated registration

Public offices held:


Public offices held: Shona Kinley

List of Public Offices Held
Position Period Held Last Date Designated Public Office Held
Special Assistant
Health Canada, Minister's Office 		January 1996 to June 1996 Not a designated office

Date Modified: